Back to Search Start Over

Colorectal cancer survival in Mexico: Leveraging a national health insurance database.

Authors :
Lozano-Esparza S
Sánchez-Blas HR
Huitzil-Meléndez FD
Meneses-Medina MI
Van Loon K
Potter MB
Mohar A
Lajous M
Source :
Cancer epidemiology [Cancer Epidemiol] 2025 Feb; Vol. 94, pp. 102698. Date of Electronic Publication: 2024 Nov 21.
Publication Year :
2025

Abstract

Purpose: We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with Seguro Popular.<br />Methods: We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by Seguro Popular (Mexico's public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.<br />Results: In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.<br />Conclusion: The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1877-783X
Volume :
94
Database :
MEDLINE
Journal :
Cancer epidemiology
Publication Type :
Academic Journal
Accession number :
39577055
Full Text :
https://doi.org/10.1016/j.canep.2024.102698